Mold-Tek Packaging reported a resilient Q3 FY26 with 6% volume and 14% EBITDA growth, contributing to strong 9M FY26 performance. Strategic initiatives like Hyderabad unit consolidation and the Vibe Generation MOU are set to drive future growth. While the lube segment faced headwinds, the company maintains ambitious revenue and profitability targets for FY26 and FY27, supported by new product developments and increased capacity utilization.
vs Q4 FY26
| Metric | Value | YoY |
|---|---|---|
| 9M FY26 Sales Value Growth | 0.12% | +12.0% YoY |
| 9M FY26 EBITDA Growth | 0.2% | +20.0% YoY |
| Q3 FY26 Sales Volume Growth | 0.06% | +6.0% YoY |
| Q3 FY26 EBITDA Growth | 0.14% | +14.0% YoY |
| 9M FY26 PAT | ₹52.25 Cr | +18.0% YoY |
| 9M FY26 EPS | ₹15.75 | — |
Segment Breakdown
Share of EBITDA per kg
| Metric | Latest | Trend |
|---|---|---|
| Volume Growth | 0.07% | |
| EBITDA per kg(Rs) | 40.7 |
| Category | Headline | |
|---|---|---|
Capex | ₹120 crores cut — implied from previous year's capex |
| Category | Target | Priority |
|---|---|---|
| Revenue | FY26 Topline→INR870 crores | High |
| Revenue | FY27 Topline→INR1,000 crores | High |
| Volume | FY27 Volume Growth→12 to 15% | High |
| EBITDA | FY26 EBITDA→INR170 crores | High |
| EBITDA | FY27 EBITDA→INR200-215 crores | High |
| PAT | FY26 PAT→INR73-75 crores | High |
| PAT | FY27 PAT Growth→20% | High |
| Pharma Revenue | FY26 Pharma Revenue→INR35 crores | High |
| Pharma Revenue | FY27 Pharma Revenue→INR50-55 crores | High |
| Pharma Volume Growth | Long-term Pharma Volume Growth→30-35% | Medium |
| Capacity Utilization | ABG Capacity Utilization→above 70% | High |
| Capacity Utilization | Overall Capacity Utilization→above 70% | High |
| Revenue Potential | Revenue Potential (current machinery)→INR1,000 crores | High |
| Revenue Potential | Revenue Potential (with planned machines)→INR1,150-1,200 crores | High |
| Capex | FY27 Capex→INR80-85 crores | High |
| # | Metric | |
|---|---|---|
| 01 | Vibe Generation product commercialization | |
| 02 | Pharma segment revenue growth | |
| 03 | Sultanpur Hyderabad unit consolidation benefits | |
| 04 | Asian Paints volume growth | |
| 05 | Swiggy MOU volume contribution |
| Severity | Risk |
|---|---|
medium | Q3 seasonality and extended rainfall Q3 is traditionally the weakest quarter, and this year was further impacted by extended rainfall, affecting overall growth rates. Management |
medium | Competition in the lubricant segment and loss of BPCL tender The company lost the BPCL tender due to aggressive pricing by competitors and is strategically exiting low-grade lubricant markets, leading to a 10% volume decline in Q3. Management |
low | Uncertainty of US tariffs impacting Pharma volumes Q3 Pharma volumes were impacted by uncertainty regarding US tariffs, though management believes this is now clarified and volumes will pick up. Management |
low | Challenges in achieving very high capacity utilization in injection molding Product mix variations and non-fungibility of jar/lid manufacturing make it difficult to consistently achieve capacity utilization above 75% without impacting efficiency. Management |
Mold-Tek Packaging reported a robust performance for the nine months ending Q3 FY26, with EBITDA increasing by 20% and sales value by 12% compared to the previous nine months. For Q3 FY26 specifically, sales volumes grew by 6% and EBITDA by 14% year-on-year. Despite Q3 traditionally being the weakest quarter, the company observed double-digit growth in January and expects strong order books for February, anticipating a return to 12-15% volume growth in Q4 FY26 and Q1 FY27.
The company has largely completed the consolidation of its Hyderabad manufacturing units, reducing them from five to two (Unit 1 and 10). The printing unit and Unit 4 (catering to Asian Paints) are also being moved to Sultanpur. This consolidation is expected to yield better operational efficiencies, cost controls, and reduced movement of goods and personnel, with visible impacts anticipated from Q4 FY26 onwards.
Mold-Tek has signed an MOU with Vibe Generation to develop unique product patents for closures and other applications. The first two component drawings are complete, and pilot molds are expected by the end of February/March 2026. Commercial molds are targeted for Q1 FY27, with these products having applications in both European and Indian markets, potentially adding tens of crores in value over the next year. Additionally, the company is developing new Pharma products like eye drops and nasal sprays, with pilot molds for ophthalmic products already under development.
The Pharma segment has cleared over 25 clients for production, though less than half have started commercial pickup. The company aims to achieve INR35 crores in Pharma revenue for FY26 and targets INR50-55 crores for FY27, representing a 40-45% growth. Long-term, Pharma is expected to grow at 30-35% volume, significantly contributing to the bottom line as it operates above the break-even point.
The company expects to close FY26 with ABG volumes around 6,000 tons, with capacity utilization projected to exceed 70% in FY27. The resolution of Recycled Content Plastic (RCP) issues with Asian Paints has led to volumes picking up from January, with a formula developed to incorporate 40-50% RCP. Management clarified that the use of cheaper RCP will not impact EBITDA per kg as the cost benefit will be passed on to clients, ensuring competitiveness.
The lubricant segment experienced a 10% volume decline in Q3 FY26. This was primarily due to the loss of the BPCL tender and a strategic decision to not actively participate in the low-grade, urea-based DEF lubes market. The company is letting go of low-end lube opportunities and expects the segment to see 2-3% annual growth, aligning with private players. The addition of Veedol recently is expected to partially fill the gap from the BPCL tender loss.
FY26 capex is projected to be around INR120 crores, down from INR140 crores in FY25, with a target of INR80-85 crores for FY27. This capex includes INR25 crores for Pharma expansion, INR20-25 crores annually for tool room and mold replacement, and INR9 crores for injection molding machines, particularly for the North plant's Thin-wall and Q-Pack products. Overall capacity utilization in Q3 FY26 was 62.5%, down from 74% in Q1, but is expected to cross 70% in Q4 FY26 and remain above 70% in FY27 due to increased utilization of ABG facilities and North plant products.
Mold-Tek has been selected as a preferred vendor for Swiggy restaurants, providing restaurant and food packs. This partnership is expected to generate EBITDA per kg similar to their Food and FMCG segment (INR70-80 per kg). While it is a recent MOU and significant volume additions are not expected immediately, it will enable broader reach to restaurants and food delivery partners, contributing to growth in the coming quarters.